Growth Metrics

Biogen (BIIB) Cash & Current Investments (2016 - 2026)

Biogen has reported Cash & Current Investments over the past 18 years, most recently at $4.3 billion for Q1 2026.

  • For Q1 2026, Cash & Current Investments rose 64.83% year-over-year to $4.3 billion; the TTM value through Mar 2026 reached $4.3 billion, up 64.83%, while the annual FY2025 figure was $3.8 billion, 60.66% up from the prior year.
  • Cash & Current Investments for Q1 2026 was $4.3 billion at Biogen, up from $3.8 billion in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $6.1 billion in Q2 2023 and troughed at $1.0 billion in Q4 2023.
  • A 5-year average of $3.4 billion and a median of $3.8 billion in 2022 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: tumbled 78.69% in 2024 and later soared 141.84% in 2025.
  • Year by year, Cash & Current Investments stood at $4.9 billion in 2022, then crashed by 78.54% to $1.0 billion in 2023, then soared by 126.21% to $2.4 billion in 2024, then surged by 60.66% to $3.8 billion in 2025, then increased by 12.24% to $4.3 billion in 2026.
  • Business Quant data shows Cash & Current Investments for BIIB at $4.3 billion in Q1 2026, $3.8 billion in Q4 2025, and $4.0 billion in Q3 2025.